Abstract
OBJECTIVE: To compare GnRH agonist down-regulated donor-oocyte/recipient cycle outcomes using intramuscular (IM-MEDS; urinary human chorionic gonadotropin + Repronex®) vs. subcutaneous (SQ-MEDS; recombinant hCG (Ovidrel®) + Menopur®) administration of medications.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
